ESTRO 2024 - Abstract Book

S1553

Clinical - Lower GI

ESTRO 2024

Recurrence rates for TAMIS-RT/RTQT versus radical surgery were: local (17% vs 3%; p=0.075), nodal: (4% vs 0%; p=NS), distant metastases (13% vs 6%; p=NS).

The 5-year OS (figure 1) , DFS, LRFS (figure 2) , NRSFS and DMFS for TAMIS with adjuvant treatment vs radical surgery were 81% vs 96% p=0.194, 85% vs 96% p=0.392, 77% vs 100% p=0.021, 100% vs 90% p=0.192, 88% vs 94% p=0.286, respectively.

In the survival analysis, stratifying by pT stage, TAMIS-RT/RTQT had a worse 5-year LRFS compared to radical surgery (pT1: 80% vs 100% and pT2: 66% vs 100%; p=0.017, respectively)

The most common adverse events observed in TAMIS-RT/RTQT group compared to the radical surgery group, as assessed by the CTCAEv.5 scale, were: fecal incontinence (26% vs. 14%), stoma (13% vs. 34%), rectal hemorrhage (13% vs. 17%) and nausea (9% vs. 57%) respectively.

In addition, the mean length of hospital stay was 4 days (1-11) versus 12 days (5-31), respectively, p=0.034.